Skip to main content
. 2015 Oct 19;6(41):43508–43528. doi: 10.18632/oncotarget.6180

Figure 5. Archazolid A inhibits Notch1 signaling.

Figure 5

A. Hes1 mRNA expression of Jurkat cells treated with Archazolid A (Arch, 10 nM, 24h) or DBZ (50 μM, 24h) is shown. Archazolid A: paired t-test, *p = 0.0341, n = 3. DBZ: paired t-test, *p = 0.0090, n = 3. B. Immunoblots from Jurkat cells treated with Archazolid A (Arch, 10 nM, left panel) or DBZ (10 μM, right panel) for the indicated times and probed with antibodies for Notch, NICD, and c-myc are shown. Immunoblots for β-tubulin indicate equal loading. Bar graphs display quantitative evaluations of immunoblots for Notch1, NICD, and c-myc. n = 3. C. Immunoblots from PDX cells treated with Archazolid A (10 nM, 24h) and probed with antibodies for NICD are shown. Ponceau staining is used as loading control. D. Immunostainings from Jurkat cells treated with Archazolid A (Arch, 10 nM, 24h) or DBZ (50 μM, 24h) for NICD (green, left panels) and Notch1 (green, right panels) are shown. n = 3. Scale bar 10 μm. Bar graphs display quantitative evaluations of NICD and Notch1 intensities. E. Immunostainings from Jurkat cells treated with Archazolid A (Arch, 10 nM, 24h) for LAMP1 (red) and Notch1 (green) are shown. Merged pictures indicate colocalization of LAMP1 and Notch1 (yellow). n = 3. Scale bar 10 μm.